CagriSema: The Next Generation Dual-Hormone Weight Loss Treatment

Novo Nordisk’s CagriSema combines long-acting amylin analog cagrilintide with GLP-1 receptor agonist semaglutide in one once-weekly injection. It is being developed for weight management and type 2 diabetes. Semaglutide already has approved products, but the combination remains investigational. Its research does not establish instructions to mix or overlap separately purchased preparations.

Supporting references: GLP-1 receptor; amylin.

Semaglutide activates GLP-1 receptors, supporting glucose-dependent insulin release, slowing gastric emptying and reducing appetite. Cagrilintide supplies an amylin-related satiety signal, with additional effects on stomach emptying and glucagon release. The pairing therefore tests complementary appetite and blood-glucose mechanisms. Outcomes must still be judged from the named trials, rather than inferred from the biological rationale.

REDEFINE 1 enrolled 3,417 adults with obesity or overweight plus a weight-related condition, without diabetes, for 68 weeks. CagriSema 2.4/2.4 mg produced 20.4% mean weight reduction versus 3.0% placebo under the treatment-policy analysis, which counts participants regardless of adherence or other weight-loss treatment. The adherence-assuming trial-product analysis found 22.7% versus 2.3%. The two estimates answer different questions; they are not rounding variants.

REDEFINE 2 studied obesity with type 2 diabetes and reported approximately 14% mean loss versus about 3% placebo, with most participants reaching their blood-sugar target. REDEFINE 1 was positive against placebo but below the roughly 25% loss that markets had expected. An individual’s expected response cannot be read directly from these trial averages.

Supporting references: REDEFINE 1; REDEFINE 2; 22.7% figure assumed all participants stayed on treatment; mean body weight change was -20.4%.

REDEFINE 4 was an 84-week, open-label randomized comparison in 809 participants using CagriSema 2.4/2.4 mg and tirzepatide 15 mg. The sponsor reported 23.0% versus 25.5% loss under its efficacy estimand, and 20.2% versus 23.6% under the treatment-regimen analysis. CagriSema did not meet the primary non-inferiority endpoint. These outcomes were company-reported and not yet peer-reviewed in the dated report.

Separate-trial figures—20.4% at 68 weeks for CagriSema in REDEFINE 1 and 20.9% at 72 weeks for tirzepatide 15 mg in SURMOUNT-1—are not a head-to-head ranking. The retained 2026 REIMAGINE 5 report compared different doses in type 2 diabetes: CagriSema 1/1 mg versus tirzepatide 5 mg produced 12.4% versus 9.1% loss at 60 weeks. Its population, doses and endpoint do not overturn REDEFINE 4.

Supporting references: 20.9% at 72 weeks; did not meet its goal of showing non-inferiority.

Novo’s September 2026 REDEFINE 9 report described 21.0% loss versus 2.0% placebo at 68 weeks with CagriSema 1/1 mg under the efficacy estimand. An October 20, 2026 post hoc REDEFINE 1 analysis reported 25.0% loss versus 3.0% placebo among women, with favorable findings across menopause groups. These results are useful emerging evidence. The women’s analysis is a subgroup finding rather than the main all-participant result; menopause categories were assigned after the fact and formal interaction testing was not performed, so it does not identify a reproductive stage with superior response.

Across REDEFINE 1 and 2, gastrointestinal events affected 72.5%–79.6% of CagriSema recipients. Nausea, vomiting, diarrhea and constipation were common; most events were described as transient and mild to moderate. In REDEFINE 1 specifically, gastrointestinal events occurred in 79.6% versus 39.9% placebo, and adverse-event discontinuation in 5.9% versus 3.5%. These group results do not promise a fixed recovery week or individual tolerance.

Semaglutide’s product information includes acute gallbladder disease, including gallstones, and acute pancreatitis, together with a boxed warning concerning thyroid C-cell tumors in rodents. It is not used in people with a personal or family history of medullary thyroid carcinoma. Cagrilintide’s 2024 thorough-QT study in healthy participants found no clinically relevant QTc prolongation. Severe persistent abdominal pain or inability to retain fluids warrants assessment; the evidence here does not provide blanket pancreatitis clearance, a universal thyroid-testing rule or a switching schedule.

The principal REDEFINE 1 and 2 results do not report lean mass. Across GLP-1-based treatments more generally, reported lean-mass reduction ranges from about 15% or less to 40%–60% of total weight lost, depending on population and compound. MRI work suggests skeletal-muscle changes can be largely adaptive to the weight lost. Those general observations are not a measured CagriSema-specific lean-mass result.

Supporting references: 72.5%; label warns of acute gallbladder disease; showed no clinically relevant QTc prolongation; range from about 15% or less.

The company filed its CagriSema application in the fourth quarter of 2025; retained site reporting specifies December 2025. The September 2026 report anticipated review around the turn of 2026–2027, while the company’s October 20 update expected a Q4 2026 decision. These are dated expectations, not approval or a guaranteed launch.

The combination remains unapproved in the reported regulatory context, with US access limited to eligible participants in active registered trials. FDA says cagrilintide cannot be compounded under federal law. There is no established final label, commercial price, coupon, insurance benefit or launch sequence here. Any future coverage would depend on the actual label, plan, formulary, exclusions and authorization requirements.

Supporting references: submitted it to the FDA; cannot be used in compounding under federal law.